

# Diminished 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Activity Is Associated With Decreased Weight and Weight Gain Across the First Year of Life

Rogers, S. L. , Hughes, B. A. , Jones, C. A. , Freedman, L. , Smart, K. , Taylor, N. , Stewart, P. M. , Shackleton, C. H. L. , Krone, N. P. , Blissett, J. and Tomlinson, J. W.

**Author post-print (accepted) deposited in CURVE October 2016**

**Original citation & hyperlink:**

Rogers, S. L. , Hughes, B. A. , Jones, C. A. , Freedman, L. , Smart, K. , Taylor, N. , Stewart, P. M. , Shackleton, C. H. L. , Krone, N. P. , Blissett, J. and Tomlinson, J. W. (2014) Diminished 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Activity Is Associated With Decreased Weight and Weight Gain Across the First Year of Life. *The Journal of Clinical Endocrinology & Metabolism*, volume 99 (5): E821-E831

<http://dx.doi.org/10.1210/jc.2013-3254>

DOI 10.1210/jc.2013-3254

ISSN 0021-972X

ESSN 1945-7197

Publisher: Endocrine Society

**Copyright © and Moral Rights are retained by the author(s) and/ or other copyright owners. A copy can be downloaded for personal non-commercial research or study, without prior permission or charge. This item cannot be reproduced or quoted extensively from without first obtaining permission in writing from the copyright holder(s). The content must not be changed in any way or sold commercially in any format or medium without the formal permission of the copyright holders.**

**This document is the author's post-print version, incorporating any revisions agreed during the peer-review process. Some differences between the published version and this version may remain and you are advised to consult the published version if you wish to cite from it.**

# Diminished 11 $\beta$ -Hydroxysteroid Dehydrogenase Type 2 Activity Is Associated With Decreased Weight and Weight Gain Across the First Year of Life

Samantha L. Rogers, Beverly A. Hughes, Christopher A. Jones, Lauren Freedman, Katherine Smart, Norman Taylor, Paul M. Stewart, Cedric H. L. Shackleton, Nils P. Krone, Jacqueline Blissett\*, and Jeremy W. Tomlinson\*

Address all correspondence and requests for reprints to: Professor Jeremy W. Tomlinson, PhD, FRCP, Professor of Endocrinology and Medical Research Council Senior Clinical Fellow, Centre for Endocrinology, Diabetes, and Metabolism, School of Clinical and Experimental Medicine, Institute of Biomedical Research, University of Birmingham, Queen Elizabeth Hospital, Birmingham B15 2TT, United Kingdom. E-mail: [j.w.tomlinson@bham.ac.uk](mailto:j.w.tomlinson@bham.ac.uk).

\*J.B. and J.W.T. contributed equally to this work.

DOI: <http://dx.doi.org/10.1210/jc.2013-3254>

Received: August 23, 2013

Accepted: January 06, 2014

Published Online: February 11, 2014

## Context:

Low birth weight is associated with adverse metabolic outcome in adulthood. Exposure to glucocorticoid (GC) excess in utero is associated with decreased birth weight, but the prospective longitudinal relationship between GC metabolism and growth has not been examined.

## Objective:

We have hypothesized that changes in GC metabolism leading to increased availability may impair growth.

## Design:

This was a prospective, longitudinal study with clinical measurements and 24-hour urinary steroid metabolite analysis at 1, 4, 12, 26, and 52 weeks after delivery in mothers and their babies.

## Setting:

The study was conducted with observations and samples collected in the volunteers' own homes.

## Participants:

Healthy mothers and newborn babies/infants participated in the study.

## Interventions:

There were no interventions.

## Main outcome measures:

Urinary steroid metabolite excretion quantified by gas chromatography/mass spectroscopy across the first year of life in relation to change in weight was measured.

## Results:

The total production of the GC metabolites quantified increased across the first year of life. Markers of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 activity increased from the age of 3 months as did those of 5 $\alpha$ -reductase activity. After correcting for confounding variables, low markers of 11 $\beta$ -hydroxysteroid dehydrogenase type 2 activity was associated with reduced absolute weight and decreased weight

gain over the first year of life. In the mothers, 5 $\alpha$ -reductase activity was low at birth and progressively increased to normal over the first 6 months postpartum.

### Conclusions:

Increased GC exposure as a consequence of reduced 11 $\beta$ -hydroxysteroid dehydrogenase type 2 activity is likely to be a critical determinant of growth in early life. This not only highlights the central role of GCs and their metabolism, but also emphasizes the need for detailed longitudinal analyses.

There is a wealth of epidemiological evidence to support the hypothesis that low-birth-weight infants are predisposed to metabolic disease in adult life (1). Despite this, and faced with the global epidemic of obesity, diabetes mellitus, and metabolic disease, identification of the mechanisms underpinning this observation have remained elusive. The adrenal gland is responsible for the coordinated and highly regulated secretion of glucocorticoids (GCs), mineralocorticoids, and androgens, including dehydroepiandrosterone. Changing patterns of corticosteroid secretion and metabolism have been described in many common conditions including obesity and insulin resistance in children and adults (2–4). In utero, exposure to exogenous GCs at high doses, although often clinically indicated, can also have detrimental effects, including transient hyperinsulinemia in neonates (5), impaired vascular function, and reduced pancreatic  $\beta$ -cell function later in life (6). In rodent models, GC exposure decreases birth weight as well as inducing dysglycemia and insulin resistance in the offspring (7, 8), potentially delaying pubertal development (8).

The regulation of GC action is complex and not simply determined by circulating concentrations. At a prereceptor level, the isozymes of 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ -HSD) are able to interconvert inactive cortisone and active cortisol. 11 $\beta$ -HSD type 1 (11 $\beta$ -HSD1) is expressed in liver, adipose tissue, muscle, and bone and regenerates cortisol from cortisone. In contrast, 11 $\beta$ -HSD type 2 (11 $\beta$ -HSD2) is expressed in mineralocorticoid target tissues, including kidney and large bowel, in which it inactivates cortisol to cortisone and thereby ameliorates the action of cortisol to bind and activate the mineralocorticoid receptor, for which it shares a similar affinity to aldosterone. Genetic defects in 11 $\beta$ -HSD2 cause the syndrome of apparent mineralocorticoid excess (AME), which can present with uncontrolled hypertension and life-threatening hypokalemia in childhood and in addition is associated with low birth weight (9). Furthermore, decreased placental 11 $\beta$ -HSD2 gene expression has been implicated in the pathogenesis of intrauterine growth restriction (10).

In parallel, the A-ring reductases, 5 $\alpha$ -reductase types 1 and 2, (5 $\alpha$ R1 and 5 $\alpha$ R2) and 5 $\beta$ -reductase convert cortisol and cortisone to their dihydrometabolites, and these are subsequently converted to tetrahydrometabolites through the action of 3 $\alpha$ -hydroxysteroid dehydrogenase. In addition, 5 $\alpha$ -reductase (largely 5 $\alpha$ R2) is crucial for converting T to the more potent androgen, dihydrotestosterone, and genetic defects in 5 $\alpha$ R2 lead to 46XY disorder of sexual differentiation; genetic defects in 5 $\alpha$ R1 have not been described. The role of the A-ring reductases in neonatal and infant growth and development has not been explored.

In this study, we have tested the hypothesis that increased cortisol exposure through increased 11 $\beta$ -HSD1, decreased 11 $\beta$ -HSD2 or decreased A-ring reductase activity, individually or in combination, contributes to changes in growth and development across the first year of life. To answer this question, we designed a prospective longitudinal study to characterize corticosteroid metabolite profiles in a cohort of healthy babies and their mothers across the first year of life.

## Materials and Methods

### Clinical Protocol

The clinical protocol received full ethical approval from Birmingham East, North, and Solihull Research Ethics Committee, United Kingdom (reference number 10/H1206/67). Research and development approval was granted by Birmingham Women's National Health Service Foundation Trust (reference number 10/BWH/NO95).

Recruitment took place on low-risk maternity units in Birmingham, West Midlands, United Kingdom, and women without complications during pregnancy and labor were identified and approached; fully informed written consent was obtained. Mothers and infants were visited at 1 week, 1 month, 3 months, 6 months, and 12 months postpartum. At all time points apart from 3 months, maternal and infant weight and infant length were measured. Infants were weighed without clothes. Weight was converted to a SD score (SDS), which adjusts measurements for age and gender (Child Growth Foundation, 1996). Infant length was measured to the nearest 0.5 cm using a Seca 210 mobile measuring mat. Mothers were weighed wearing light indoor clothing without shoes. Maternal height was measured at 1 week postpartum using a stadiometer.

During the 1-week home visit, mothers reported their pregnancy medical history and completed questionnaires ascertaining demographic information. At each time point, mothers provided a single maternal urine sample and a 24-hour collection of wet diapers to determine androgen and cortisol metabolites (see below).

### Extraction of urine from diapers

Diapers in the 24-hour collections were counted and weighed. The wet material was removed and placed in a beaker and a measured volume of 4% saline solution was added (~1 mL/g of gel). The samples were squeezed by hand for 5 minutes and then left at 4°C overnight to equilibrate. The diaper extract was then put through a potato ricer containing a square of nylon gauze and the liquid collected and filtered through glass wool to remove residual particles of gel. The samples were then analyzed as described below. The total volume of the collection was calculated from the equation: total volume (milliliters) = [weight of wet diapers (grams) – expected total weight of dry diapers (grams)] + total amount of saline added. Prior development established that disposable diapers consist of cellulose fluff containing supersorb granules (polyacrylate resin) and that there were no material differences between the major brands, eg, Pampers (Proctor and Gamble) and Huggies (Kimberly-Clark). Pure samples of the resin were shown not to selectively retain steroids. The saline concentration was established at 4% to minimize gel swelling. Experiments involving dripping urine onto new diapers established that steroid recovery was close to 100%. The dry weight of a given diaper type was established by weighing 20 examples and obtaining the mean. Dry diaper weights were small in relation to the urine weight and showed low variation. Therefore, possible errors in the calculated urine volume (due to an inaccurate estimation of dry diaper weight) were considered to be negligible.

### Urinary steroid analysis

Urinary androgen and corticosteroid metabolite analysis was performed by gas chromatography/mass spectroscopy as described previously (4, 11). Briefly, free and conjugated steroids were extracted from urine by solid-phase extraction. Steroids were enzymatically released from conjugation and reextracted. An internal standard (stigmastrol) was added prior to derivitization to form methyloxime-trimethylsilyl ethers. The final derivative was dissolved in cyclohexane, which was transferred to a gas chromatography/mass spectroscopy autosampler vial. The samples were run on an Agilent 5973 instrument in selected ion monitoring mode. It should be stated that only a few classical cortisol (F) metabolites were measured, dependent on their availability as authentic compounds necessary for instrument calibration. Newborns in particular have important metabolites that were not included, especially 1β- and 6α-hydroxylated metabolites of tetrahydrocortisone and the cortolones (12). In this document, use of the term, total F metabolites (see definition below), means the total of measured metabolites, not the complete excretion of all metabolites. We have estimated that the percentage of measured metabolites as compared with the complete excretion of all metabolites is approximately

49% at 1 week of age, 60% at 1 month, 74% at 3 months, 85% at 6 months, and 91% at 12 months of age.

#### **Interpretation of totals and indices of urinary steroid excretion**

The sum of total cortisol metabolites [tetrahydrocortisol (THF), tetrahydrocortisone (THE), 5 $\alpha$ -THF,  $\alpha$ -cortolone, cortisone (E), F,  $\beta$ -cortolone,  $\beta$ -cortol,  $\alpha$ -cortol] provides a reflection of cortisol secretion rate (total F metabolites). The ratio of tetrahydrometabolites of cortisol (THF + 5 $\alpha$ THF) to those of cortisone (THE) provides a reflection of 11 $\beta$ -HSD1 activity when considered with the ratio of urinary F to E, which more accurately reflects renal 11 $\beta$ -HSD2 activity (higher F to E ratios indicative of decreased 11 $\beta$ -HSD2 activity). Urinary free F and E, which provide the most accurate assessment of 11 $\beta$ -HSD2 activity were not measured (11, 13), although our own in-house analysis has shown a good correlation between hydrolyzed (free measurements) and nonhydrolyzed samples (cortisol  $r = 0.80$ , cortisone  $r = 0.71$ ). In addition, the ratio of cortols to cortolones reflects 11 $\beta$ -HSD1 activity. Evidence to support the interpretation of these ratios is provided from studies using selective 11 $\beta$ -HSD1 inhibitors and patients with mutations causing functional defects in 11 $\beta$ -HSD1 (14, 15). The activities of 5 $\alpha$ - and 5 $\beta$ -reductases can be inferred from measuring the ratio of 5 $\alpha$ THF to THF and androsterone (An) to etiocholanolone (Et).

#### **Creatinine assay**

Creatinine was measured using a QuantiChrom creatinine assay kit (BioAssay Systems), which is designed to measure creatinine directly in biological samples without any pretreatment. The assay is based on a kinetic Jaffe reaction, which uses picrate that forms a red-colored complex with creatinine. The intensity of the color, measured at 510 nm, is directly proportional to creatinine concentration in the sample.

#### **Statistical approach**

Data are presented as median and interquartile range (IQR) unless otherwise stated. Statistical analysis was undertaken using the R software language and the mixed-effects models were calculated using the LME4 package (<http://cran.r-project.org/package=lme4>); the Markov Chain Monte Carlo estimates of the random effects parameters and confidence intervals were calculated using the languageR package. Data were modeled using a mixed fixed and a random factor linear effects model, which used random effects to model those sources of variation attributable to the design of the study. In this model, time of measurement and type of steroid were treated as random factors within a random intercept model. Because each of the steroid levels was measured on a different metric, these data were standardized to z-scores prior to the subsequent analysis. For infant samples, the additional effect of gender was incorporated in to the statistical models to determine the two-way interactions (eg, gendersteroid and gendertime) and three-way interactions effect (eg, gendertimesteroid). Detailed statistical methods and model descriptions are presented in Supplemental Tables 1–4.

## **Results**

Fifty-nine mothers [mean age  $29 \pm 5$  y, mean body mass index (BMI)  $26.9 \pm 3.9$  kg/m<sup>2</sup>] and their infants [36 males, 23 females; mean birth weight 3.51 kg (SD 0.36)] were recruited from low-risk maternity units after delivery (all provided informed written consent). Thirty-four percent (20 of 59) were in their first pregnancy, 19% (11 of 59) continued to smoke during pregnancy, and 24% (14 of 59) consumed alcohol, although all within recommended limits. None had any significant past medical history and none were taking any regular medication. Any mother with gestational diabetes, preeclampsia, or pregnancy-induced hypertension was excluded from the study. Infants born prematurely (prior to 36 wk gestation) or small for gestational age were not eligible for this study. All births were spontaneous normal vaginal deliveries without complications. Birth weight (absolute and SDS) and growth across the first year of life of the neonatal/infant cohort are presented in Table 1. Steroid ratios from one infant were excluded from the analysis because the ratios reflecting the 5 $\alpha$ -reductase activity were more than 2 SD above the mean.

**Table 1.** Changes in Weight and Length Over the First Year of Life in a Cohort of Healthy Babies

Sex	Birth		1 Week		1 Month		6 Months		12 Months	
	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
n	37	22	29	11	29	14	24	13	29	20
Age at visit, wks			1.3 ± 0.3	1.3 ± 0.4	4.8 ± 0.6	4.7 ± 0.5	26.7 ± 1.3	26.9 ± 0.7	53.1 ± 1.9	53.3 ± 1.8
Weight, kg	3.54 ± 0.39	3.46 ± 0.30	3.56 ± 0.38	3.41 ± 0.32	4.63 ± 0.47	4.28 ± 0.39	8.28 ± 1.11	7.63 ± 0.81	10.4 ± 1.36	9.37 ± 1.01
Weight SDS	0.13 ± 0.77	0.38 ± 0.71	-0.5 ± 0.75	-0.53 ± 0.64	0.05 ± 0.78	-0.05 ± 0.71	0.13 ± 1.25	0.03 ± 0.99	0.15 ± 1.27	-0.23 ± 1.07
SDS weight gain 1 to 12 mo									0.13 ± 1.27	-0.30 ± 1.13
Length, cm	52.2 ± 2.7	51.9 ± 2.3	53.6 ± 2.2	53.1 ± 1.7	58.4 ± 2.5	56.6 ± 1.6	73.1 ± 2.9	70.0 ± 2.4	79.4 ± 2.7	77.2 ± 3.2
Length SDS	0.74 ± 1.25	1.12 ± 1.47	0.70 ± 1.07	0.98 ± 0.85	1.59 ± 1.17	1.34 ± 0.77	2.36 ± 1.26	1.81 ± 1.08	1.42 ± 1.13	1.18 ± 1.33

Data presented are mean ± SD. Although urine samples were collected at 3 months, clinical parameters were not measured.

#### Changes in corticosteroid metabolism across the first year of life

There were no significant differences in steroid metabolites or their ratios between boys and girls, and therefore, the analysis against time of the complete cohort is presented. The absolute data divided according to gender are presented in Supplemental Table 5. Steroid excretion data are summarized in Figure 1 and Table 2.

**Figure 1.** Neonatal and infant cortisol metabolite production (micrograms per 24 h) (A) and urinary steroid metabolite ratios (B–F) across the first year of life. The F to E ratio (B) reflects 11β-HSD2 activity; 5αTHF+THF to THE (C) and cortol to cortolone ratios (D) ratios reflect 11β-HSD1 activity and 5αTHF to THF (E) and An to Et (F) ratios reflect 5α-reductase activity. DHEA, dehydroepiandrosterone. There was no impact of gender on the patterns of change in steroid hormone metabolites with time, and *P* values reflect the interaction of individual steroid metabolites or ratios (boys and girls combined) with time.

**Table 2.** Longitudinal 24-Hour Urinary Steroid Metabolite Analysis in a Cohort of Healthy Babies Across the First Year of Life

	<b>1 Week (n = 50)</b>	<b>1 Month (n = 56)</b>	<b>3 Months (n = 55)</b>	<b>6 Months (n = 49)</b>	<b>12 Months (n = 47)</b>
Total F metabolites					
Median	280.7	539.8	767.9	970.6	999.4
IQR	273.1	405.0	602.2	639.3	852.9
THF					
Median	1.50	2.35	15.1	51.6	87.7
IQR	1.93	2.47	12.5	48.3	94.9
5 $\alpha$ -THF					
Median	0.97	5.76	95.1	260.6	255.6
IQR	2.05	11.25	96.7	207.6	293.0
THE					
Median	188.8	309.1	404.1	382.2	382.7
IQR	157.9	247.7	397.2	278.4	398.4
Cortisol					
Median	10.5	11.4	9.4	8.0	10.7
IQR	10.3	10.0	5.6	6.4	15.3
Cortisone					
Median	17.7	26.4	20.6	18.2	16.6
IQR	20.1	24.7	12.9	11.4	18.4
$\alpha$ -Cortol					
Median	7.9	18.1	14.1	19.1	26.3
IQR	9.1	22.5	12.7	14.9	25.6
$\beta$ -Cortol					
Median	1.8	4.1	12.5	27.1	50.0
IQR	2.1	4.4	11.4	23.9	63.7

	<b>1 Week (n = 50)</b>	<b>1 Month (n = 56)</b>	<b>3 Months (n = 55)</b>	<b>6 Months (n = 49)</b>	<b>12 Months (n = 47)</b>
$\alpha$ -Cortolone					
Median	7.8	25.8	40.3	55.3	71.3
IQR	13.4	26.1	27.7	30.7	69.6
$\beta$ -Cortolone					
Median	49.9	118.5	126.5	93.5	82.2
IQR	64.7	128.2	125.4	75.5	97.1
An					
Median	2.1	4.4	4.1	3.6	3.8
IQR	2.0	5.3	4.3	3.6	7.3
Et					
Median	0.73	0.67	0.55	0.62	1.75
IQR	0.69	0.71	0.53	0.49	2.50
DHEA					
Median	2.83	2.82	1.47	0.85	0.91
IQR	3.04	3.79	1.69	1.02	1.60
16 $\alpha$ -OH-DHEA					
Median	191.6	294.0	57.9	14.3	5.1
IQR	437.7	546.1	65.2	20.4	11.2
F to E ratio					
Median	0.53	0.38	0.47	0.50	0.70
IQR	0.31	0.16	0.13	0.19	0.34
(THF+5 $\alpha$ THF) to THE ratio					
Median	0.02	0.03	0.35	0.91	0.95
IQR	0.01	0.03	0.29	0.48	0.45
Cortol to cortolone ratio					
	0.16	0.16	0.17	0.34	0.53



		<b>1 Week (n = 50)</b>	<b>1 Month (n = 56)</b>	<b>3 Months (n = 55)</b>	<b>6 Months (n = 49)</b>	<b>12 Months (n = 47)</b>
Median						
	IQR	0.10	0.17	0.16	0.13	0.20
5 $\alpha$ THF to THF ratio						
Median		0.86	3.33	6.71	4.92	2.71
	IQR	0.70	2.56	3.47	3.27	1.36
An to Et ratio						
Median		2.74	6.25	7.53	5.51	2.63
	IQR	2.70	5.38	6.32	2.98	1.58

Abbreviations: DHEA, dehydroepiandrosterone; OH-DHEA, hydroxydehydroepiandrosterone. Data presented are median with the IQR. Individual steroid metabolites are quoted in micrograms per 24 hours. Statistical analysis was performed using Wald type II  $\chi^2$  tests of deviation for the time by steroid interaction. There was no impact of sex on the statistical modeling.

Total cortisol metabolites increased across the first year of life ( $P < .00001$ ) (Table 2 and Figure 1). However, this must be interpreted with caution because the proportion of quantified metabolites increased with time (see *Materials and Methods*). 11 $\beta$ -HSD1 activity, reflected by the 5 $\alpha$ THF+THF to THE and cortol to cortolone ratios, was almost undetectable until 3 months of age and then increased dramatically between 3 and 6 months, with stable values at 12 months ( $P < .00001$ ) (Table 2 and Figure 1). 5 $\alpha$ -Reductase activity, as estimated by the 5 $\alpha$ THF to THF and An to Et ratios, was also low at birth, rising significantly to a peak at 3 months of age and then showing a decrease at 6 months with a further decrease at 12 months of age ( $P < .00001$ ) (Table 2 and Figure 1). Both 5 $\alpha$ - and 5 $\beta$ -reduced metabolites of cortisol (5 $\alpha$ -THF and THF, respectively) increased progressively, but the excretion of the 5 $\alpha$ -epimer was 5-fold higher (Table 2 and Figure 1). The F to E ratio also increased with time, indicative of decreasing 11 $\beta$ -HSD2 activity, although the change was less marked than that observed for 11 $\beta$ -HSD1 and 5 $\alpha$ -reductase activity ( $P < .0005$ ) (Table 2 and Figure 1).

#### Changes in maternal corticosteroid metabolite analysis postpartum

Spot urine analysis rather than 24-hour samples were analyzed and absolute corticosteroid concentrations were corrected per gram of urinary creatinine to allow for the assessment of absolute production rates. Total F metabolite production and urinary F to E ratio did not change significantly over the first 12 postpartum months. Although the cortol to cortolone ratio was weakly associated with time ( $P = .047$ , Table 3), there was no relationship with the 5 $\alpha$ THF+THF to THE, suggesting that 11 $\beta$ -HSD1 activity did not change significantly.

**Table 3.** Longitudinal Changes in Urinary Steroid Metabolite Analysis in a Cohort of Healthy Mothers in the First Postpartum Year

	<b>1 Week (n = 45)</b>	<b>1 Month (n = 53)</b>	<b>3 Months (n = 45)</b>	<b>6 Months (n = 46)</b>	<b>12 Months (n = 41)</b>
Total F metabolites					
Median	6711	7476	6661	7214	6838
IQR	2786	2552	3325	3015	2855
THF					
Median	1580	1480	1095	1229	1003
IQR	722	662	609	558	379
5 $\alpha$ -THF					
Median	265	551	793	996	831
IQR	197	451	621	781	666
THE					
Median	2326	2764	2443	2394	2363
IQR	1217	1026	174	1425	1386
Cortisol					
Median	84.0	48.0	44.0	50.5	62.0
IQR	64.5	32.5	35.0	32.0	48.5
Cortisone					
Median	108.0	77.0	69.0	87.0	120.0
IQR	76.0	40.0	42.0	43.8	92.5
$\alpha$ -Cortol					
Median	326.0	247.0	211.0	277.0	237.0
IQR	179.0	146.0	92.0	110.3	118.5
$\beta$ -Cortol					
Median	440.0	397.0	330.00	385.5	339.0
IQR	258.5	225.0	206.5	224.5	163.0

	<b>1 Week (n = 45)</b>	<b>1 Month (n = 53)</b>	<b>3 Months (n = 45)</b>	<b>6 Months (n = 46)</b>	<b>12 Months (n = 41)</b>
$\alpha$ -Cortolone					
Median	1205	1112	856	1036	1072
IQR	569	663	523	454	552
$\beta$ -Cortolone					
Median	385.0	469.0	436.0	500.0	482.0
IQR	196.0	255.5	241.0	264.8	223.0
An					
Median	583.0	679.0	1148.0	1326.0	1565.0
IQR	560.5	852.0	921.0	1092.8	1119.0
Et					
Median	1237	1261	1262	1079	1152
IQR	939	969	933	698	900
DHEA					
Median	146.0	88.0	125.0	104.0	159.0
IQR	270.0	124.0	210.5	227.3	503.0
16 $\alpha$ -OH-DHEA					
Median	244.0	212.0	246.0	240.0	400.0
IQR	480.5	279.5	378.0	298.3	645.0
F to E ratio					
Median	0.80	0.62	0.63	0.63	0.63
IQR	0.33	0.30	0.24	0.28	0.33
(THF+5 $\alpha$ THF) to THE ratio					
Median	0.86	0.79	0.90	1.02	0.77
IQR	0.32	0.26	0.33	0.36	0.22
Cortol to cortolone ratio					
	0.47	0.40	0.45	0.48	0.39

		<b>1 Week (n = 45)</b>	<b>1 Month (n = 53)</b>	<b>3 Months (n = 45)</b>	<b>6 Months (n = 46)</b>	<b>12 Months (n = 41)</b>
Median						
	IQR	0.22	0.15	0.17	0.13	0.11
5 $\alpha$ THF to THF ratio						
Median		0.18	0.39	0.75	0.87	0.89
	IQR	0.12	0.32	0.51	0.82	0.53
An to Et ratio						
Median		0.45	0.57	0.99	1.15	1.20
	IQR	0.24	0.47	0.95	0.88	0.59

Data presented are median with the IQR. Urinary corticosteroid production is expressed per grams of urinary creatinine. DHEA, dehydroepiandrosterone; OH-DHEA, hydroxydehydroepiandrosterone. Statistical analysis was performed using Wald type II  $\chi^2$  tests of deviation for the time by steroid interaction.

However, 5 $\alpha$ -, relative to 5 $\beta$ -reductase activity, reflected in the 5 $\alpha$ THF to THF and An to Et ratios was low in the immediate postpartum period and increased over the initial 3 months and then stabilized (both  $P < .00001$ , [Table 3](#)). By 12 months, values were similar to those seen in a reference cohort of women (data not shown). Changes in the 5 $\alpha$ THF to THF and An to Et ratios were driven by lower absolute concentrations of both 5 $\alpha$ THF ( $P < .0001$ ) and An ( $P < .05$ ), indicative of changes specifically in 5 $\alpha$ - rather than 5 $\beta$ -reductase activity.

#### **The relationship between maternal and neonatal/infant corticosteroid metabolism**

Partial correlation analysis was performed, adjusting for confounding variables (including infant gender and weight SDS, maternal age, BMI, and smoking) to examine any potential relationships between maternal and neonatal/infant urinary steroid metabolites; no significant relationships at any time point were identified (data not shown).

#### **Corticosteroid metabolism as a regulator of neonatal/infant growth**

Partial correlation analysis was performed adjusting for confounding variables including infant gender, maternal age and BMI, smoking during pregnancy and the age of introduction of solids. Elevation of the urinary F to E ratio at week 1, consistent with impaired 11 $\beta$ -HSD2 activity, was inversely related to weight at week 1 ( $R^2 = -0.46$ ,  $P < .01$ ). Furthermore, at 12 months of age, there was a negative relationship between F to E ratio and 12-month weight SDS ( $R^2 = -0.40$ ,  $P < .05$ ) as well as weight gain SDS over the first 12 months of life ( $R^2 = -0.51$ ,  $P < .01$ ). In addition, length SDS at 12 months was also negatively associated with F to E ratio ( $R^2 = -0.35$ ,  $P < .05$ ), suggesting that impaired 11 $\beta$ -HSD2 activity with consequent increased cortisol availability may limit growth ([Table 4](#)).

**Table 4.** Partial Correlation (2-Tailed) Analysis Examining the Relationship Between Neonatal/Infant Corticosteroid Metabolite Ratios and Weight Across the First Year of Life With Adjustment for Infant Gender, Maternal Age and BMI, Smoking During Pregnancy and the Age of Introduction of Solids (N = 31)

<b>Urinary Steroid Metabolite Ratio</b>	<b>1- Week Weight SDS</b>	<b>1- Month Weight SDS</b>	<b>6- Month Weight SDS</b>	<b>12- Month Weight SDS</b>	<b>1- to 12- Month SDS Weight Gain</b>
Concurrent F/E	-0.46 <sup>a</sup>	-0.21	-0.08	-0.40 <sup>b</sup>	-0.51 <sup>a</sup>
Concurrent THF+5 $\alpha$ THF/THE	0.09	0.03	-0.15	-0.09	-0.11
Concurrent 5 $\alpha$ THF/THF	-0.05	-0.00	-0.06	0.05	0.09
Concurrent Total F Metabolites	0.20	0.19	0.04	0.03	-0.09

aP < .01;

bP < .05.

In contrast, there was no relationship between urinary steroid metabolite ratios reflecting 11 $\beta$ -HSD1 activity, 5 $\alpha$ -reductase activity, or total GC metabolite production rate with absolute weight at the time of analysis or weight gain across the duration of the study (Table 4). However, after correcting for confounding variables, increased duration of breastfeeding was associated with higher 5 $\alpha$ -reductase activity at 6 and 12 months and increased 11 $\beta$ -HSD1 activity at 12 months (Supplemental Table 6). There were no relationships between urinary steroid metabolite ratios and smoking status (data not shown).

## Discussion

In this study, we have performed the first longitudinal characterization of corticosteroid metabolism across the first year of life. We have highlighted dramatic changes in the pattern of corticosteroid metabolite production and identified a potential role for GC metabolism, notably 11 $\beta$ -HSD2, to regulate growth and weight gain.

Both GC receptor and mineralocorticoid receptors (MR) are expressed in most tissues throughout fetal development (16, 17) and are critical to development; GC receptor knockout mice die shortly after birth (18). Clinical treatment with exogenous GC is indicated to promote organs, notably lung maturation (19), but in both human and rodent models, GC excess is associated with decreased birth weight (20–22).

We have shown that decreased 11 $\beta$ -HSD2 activity was associated with decreased weight gain across the first year of life as well as decreased length at 12 months, and it is possible that this is a reflection of decreased GC clearance. 11 $\beta$ -HSD2 is highly expressed in the human placenta, in which it serves to protect the developing fetus from high levels of active GCs. Although expressed in the fetus (16), a recent study has suggested that renal neonatal 11 $\beta$ -HSD2 activity is low in comparison with placental activity (23). In our study, the F to E ratio increased across the first year of life (suggesting decreasing 11 $\beta$ -HSD2 activity), and at 12 months, the levels were similar to those seen in the maternal cohort and to those observed in an adult control population (4); it is possible that this reflects changing patterns of enzyme expression. In our cohort, F to E ratios were, if anything, lower than those measured in the maternal samples at week 1, and this would tend to suggest increased (rather than

decreased) 11 $\beta$ -HSD2 activity in the first weeks after birth. The discrepancies in data may reflect differences in methodology, but perhaps most importantly, the use of 24-hour samples rather than spot urines. Unfortunately, we did not have access to serum or placental samples as part of this study. In rodent models, the levels of 11 $\beta$ -HSD2 correlate with fetal size (24), and there is evidence to support this in humans in whom the mRNA levels and the activity of 11 $\beta$ -HSD2 are associated with lower birth weight (25), although this is not a consistent finding in all studies (26). However, pharmacological inhibition of 11 $\beta$ -HSD2 with carbenoxolone and the genetic manipulation of 11 $\beta$ -HSD2 activity decrease birth weight (27, 28).

More than 50 different mutations in *HSD11B2*, the gene encoding 11 $\beta$ -HSD2, that cause AME have now been described (29). Cortisol and aldosterone share a similar affinity for the MR, and therefore, in the absence of 11 $\beta$ -HSD2, cortisol (which circulates at levels > 1000-fold that of aldosterone) will become the predominant ligand for the MR, leading to hypertension and hypokalemia. Several cases of AME presenting in the first year of life have been described and are associated with low birth weight, and this is believed to be due, at least in part, to increased fetal exposure to GCs (30). In our study, no child had urinary steroid metabolite ratios that would suggest undiagnosed AME, and it is possible therefore that a functional defect in 11 $\beta$ -HSD2 is responsible for the observations in this study. Although the absence of 11 $\beta$ -HSD2 activity causing low weight gain is clearly detrimental, excessive weight gain across the first year of life is also associated with adverse outcomes in childhood (31). It is possible therefore that there is a balance of activity that is optimal for growth across the first year of life, and this would need to be tested in extended longitudinal studies across childhood.

11 $\beta$ -HSD1 generates active GCs within key metabolic target tissues. In our study, activity remained low until 3 months of age and then gradually increased. This is likely to have a functional importance because case reports have been described in which neonates born with congenital adrenal hyperplasia fail to respond to inactive cortisone acetate (which requires 11 $\beta$ -HSD1 for activation to cortisol) (32). Urinary steroid metabolite assessment of 11 $\beta$ -HSD1 activity is believed to largely reflect hepatic activity. Data from preclinical studies and clinical trials of selective 11 $\beta$ -HSD1 inhibitors have demonstrated a role for 11 $\beta$ -HSD1 in the regulation of glucose and lipid metabolism (33, 34). It is plausible that the predisposition of neonates to develop hypoglycemia could arise as a result of a decreased gluconeogenesis, due to lack of ability to locally regenerate active glucocorticoids, although this hypothesis remains entirely untested. The lack of a relationship between 11 $\beta$ -HSD1 activity and growth across the first year of life is perhaps to be expected. Lack of expression and activity in the first few months of life would suggest that the contribution that 11 $\beta$ -HSD1 makes to GC exposure over this time is limited. In addition, there is no evidence from rodent models that genetic deletion of 11 $\beta$ -HSD1 impairs growth and development in the early stages of life (35).

5 $\alpha$ R1 is expressed in the neonatal liver, and this continues throughout life. In the nongenital skin, expression persists up until 2–3 years of age and then decreases but increases again around the time of puberty (36); it is thought to be contributory to pubertal virilization in patients with 5 $\alpha$ R2 deficiency. 5 $\alpha$ R2 is also expressed in the neonatal and adult liver. Expression remains in the nongenital skin for the first 2–3 years of life and then decreases, only persisting in the prostate, epididymis, seminal vesicles, and urogenital skin (37). Despite the evidence of a link between metabolic phenotype and 5 $\alpha$ R in adults (4, 38–40), we did not observe any relationship with growth in the first year. However, activity was low at birth increasing dramatically at 3 months with levels decreasing by 6 and 12 months. Our longitudinal data are in agreement with published cross-sectional analyses that have shown a similar relationship with time (41).

In addition to these direct actions of GCs, there is evidence that exposure to GC excess has a detrimental impact later in life through programming. In a variety of animal models, GC exposure during gestation can impact adult phenotype (42, 43). Blood pressure is increased and this may be driven by alterations in the pattern of corticosteroid receptor expression, changes in sympathetic innervation, and vascular reactivity (44, 45). Similarly, adult insulin sensitivity can also be altered by prenatal GC exposure, leading to altered glucose homeostasis (46) and may contribute to the

development of conditions including nonalcoholic fatty liver disease (47) and impaired pancreatic  $\beta$ -cell development (48).

Prereceptor GC metabolism has also been implicated in the programming process. Dexamethasone treatment to pregnant rodents induces hypertension in adult offspring that is associated with decreased 11 $\beta$ -HSD2 expression in the distal nephron without any significant change in MR or 11 $\beta$ -HSD1 expression (49). Although in this study we failed to demonstrate any relationship between 11 $\beta$ -HSD1 activity and growth across the first 12 months of life, GC exposure during gestation in a primate model increases 11 $\beta$ -HSD1 expression in liver and adipose tissue later in life (50) and based on rodent models and clinical studies, this may contribute to the development of an adverse metabolic phenotype (51).

The data in humans are less clear, with discrepancies in the published data as to the impact of GC administration in the first few years of life (52, 53). The impact later into adult life also remains controversial, with some studies showing a detrimental impact on blood pressure and insulin action (54, 55), but this is not a consistent finding across all studies (56). We have examined outcomes only in the first year of life, but tracking changes in metabolic and steroid metabolite phenotype as this cohort ages will prove highly informative.

In conclusion, we have demonstrated a relationship between 11 $\beta$ -HSD2 activity and weight across the first year of life, suggesting that increased GC exposure through this mechanism may limit growth. Further studies are undoubtedly warranted, not only to see whether this longitudinal relationship is maintained later into childhood but also to understand its relevance in children who were small for gestational age or born after maternal preeclampsia and pregnancy-induced hypertension.

Abbreviations:

AME	apparent mineralocorticoid excess
An	androsterone
BMI	body mass index
E	cortisone
Et	etiocholanolone
F	cortisol
GC	glucocorticoid
11 $\beta$ -HSD	11 $\beta$ -hydroxysteroid dehydrogenase
11 $\beta$ -HSD1	11 $\beta$ -HSD type 1
11 $\beta$ -HSD2	11 $\beta$ -HSD type 2
IQR	interquartile range
MR	mineralocorticoid receptors
5 $\alpha$ R1	5 $\alpha$ -reductase type 1
5 $\alpha$ R2	5 $\alpha$ -reductase type 2
SDS	SD score
THE	tetrahydrocortisone
THF	tetrahydrocortisol.

## Acknowledgments

The author contributions included the following: S.L.R., B.A.H., L.F., N.T., and K.S. generated the clinical data for the manuscript. S.L.R., C.A.J., N.T., P.M.S., C.H.L.S., N.P.K., J.B., and J.W.T. contributed to the analysis and the interpretation of the data. All authors contributed to the writing and editing of the manuscript. The study protocol was devised by J.B. and J.W.T.

This work was supported by the Medical Research Council Senior Clinical Fellowship G0802765 (to J.W.T.), Wellcome Trust Program Grant 082809 (to P.M.S.) and Economic and Social Research Council Studentship Award ES/G017786/1 (to S.L.R. and J.B.).

Disclosure Summary: The authors declare no conflicts of interest.

## References

1. Rinaudo P, Wang E. Fetal programming and metabolic syndrome. *Annu Rev Physiol.*2012;74:107–130. [CrossRef](#), [Medline](#)
2. Dimitriou T, Maser-Gluth C, Remer T. Adrenocortical activity in healthy children is associated with fat mass. *Am J Clin Nutr.* 2003;77(3):731–736. [Medline](#)
3. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH. Cortisol metabolism in human obesity: impaired cortisone→cortisol conversion in subjects with central adiposity. *J Clin Endocrinol Metab.* 1999;84(3):1022–1027. [Abstract](#), [Medline](#)
4. Tomlinson JW, Finney J, Gay C, Hughes BA, Hughes SV, Stewart PM. Impaired glucose tolerance and insulin resistance are associated with increased adipose 11 $\beta$ -hydroxysteroid dehydrogenase type 1 expression and elevated hepatic 5 $\alpha$ -reductase activity. *Diabetes.*2008;57(10):2652–2660. [CrossRef](#), [Medline](#)
5. Verhaeghe J, van Bree R, van Herck E, Coopmans W. Exogenous corticosteroids and in utero oxygenation modulate indices of fetal insulin secretion. *J Clin Endocrinol Metab.*2005;90(6):3449–3453. [Abstract](#), [Medline](#)
6. Kelly BA, Lewandowski AJ, Worton SA, et al. Antenatal glucocorticoid exposure and long-term alterations in aortic function and glucose metabolism. *Pediatrics.*2012;129(5):e1282–e1290. [CrossRef](#), [Medline](#)
7. Cleasby ME, Kelly PA, Walker BR, Seckl JR. Programming of rat muscle and fat metabolism by in utero overexposure to glucocorticoids. *Endocrinology.*2003;144(3):999–1007. [Abstract](#), [Medline](#)
8. Smith JT, Waddell BJ. Increased fetal glucocorticoid exposure delays puberty onset in postnatal life. *Endocrinology.* 2000;141(7):2422–2428. [Abstract](#), [Medline](#)
9. Mune T, Rogerson FM, Nikkilä H, Agarwal AK, White PC. Human hypertension caused by mutations in the kidney isozyme of 11 $\beta$ -hydroxysteroid dehydrogenase. *Nat Genet.*1995;10:394–399. [CrossRef](#), [Medline](#)
10. McTernan CL, Draper N, Nicholson H, et al. Reduced placental 11 $\beta$ -hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. *J Clin Endocrinol Metab.*2001;86(10):4979–4983. [Abstract](#), [Medline](#)
11. Palermo M, Shackleton CH, Mantero F, Stewart PM. Urinary free cortisone and the assessment of 11 $\beta$ -hydroxysteroid dehydrogenase activity in man. *Clin Endocrinol (Oxf).*1996;45(5):605–611. [CrossRef](#), [Medline](#)
12. Shackleton CH, Honour JW, Taylor NF. Metabolism of fetal and neonatal adrenal steroids. *J Steroid Biochem.* 1979;11(1B):523–529. [CrossRef](#), [Medline](#)
13. Remer T, Maser-Gluth C, Wudy SA. Glucocorticoid measurements in health and disease—metabolic implications and the potential of 24-h urine analyses. *Mini Rev Med Chem.*2008;8(2):153–170. [CrossRef](#), [Medline](#)
14. Lawson AJ, Walker EA, Lavery GG, et al. Cortisone-reductase deficiency associated with heterozygous mutations in 11 $\beta$ -hydroxysteroid dehydrogenase type 1. *Proc Natl Acad Sci USA.* 2011;108(10):4111–4116. [CrossRef](#), [Medline](#)



15. Courtney R, Stewart PM, Toh M, Ndongo MN, Calle RA, Hirshberg B. Modulation of 11 $\beta$ -hydroxysteroid dehydrogenase (11 $\beta$ HSD) activity biomarkers and pharmacokinetics of PF-00915275, a selective 11 $\beta$ HSD1 inhibitor. *J Clin Endocrinol Metab.* 2008;93(2):550–556. [Abstract](#), [Medline](#)
16. Condon J, Gosden C, Gardener D, et al. Expression of type 2 11 $\beta$ -hydroxysteroid dehydrogenase and corticosteroid hormone receptors in early human fetal life. *J Clin Endocrinol Metab.* 1998;83:4490–4497. [Abstract](#), [Medline](#)
17. Costa A, Rocci MP, Arisio R, et al. Glucocorticoid receptors immunoreactivity in tissue of human embryos. *J Endocrinol Invest.* 1996;19(2):92–98. [CrossRef](#), [Medline](#)
18. Cole TJ, Blendy JA, Monaghan AP, et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. *Genes Dev.* 1995;9(13):1608–1621. [CrossRef](#), [Medline](#)
19. Kattner E, Metze B, Waiss E, Obladen M. Accelerated lung maturation following maternal steroid treatment in infants born before 30 weeks gestation. *J Perinat Med.* 1992;20(6):449–457. [CrossRef](#), [Medline](#)
20. Reinisch JM, Simon NG, Karow WG, Gandelman R. Prenatal exposure to prednisone in humans and animals retards intrauterine growth. *Science.* 1978;202:436–438. [CrossRef](#), [Medline](#)
21. Bloom SL, Sheffield JS, McIntire DD, Leveno KJ. Antenatal dexamethasone and decreased birth weight. *Obstet Gynecol.* 2001;97(4):485–490. [CrossRef](#), [Medline](#)
22. Nyirenda MJ, Lindsay RS, Kenyon CJ, Burchell A, Seckl JR. Glucocorticoid exposure in late gestation permanently programs rat hepatic phosphoenolpyruvate carboxykinase and glucocorticoid receptor expression and causes glucose intolerance in adult offspring. *J Clin Invest.* 1998;101(10):2174–2181. [CrossRef](#), [Medline](#)
23. Martinerie L, Pussard E, Meduri G, Delezoide AL, Boileau P, Lombes M. Lack of renal 11 $\beta$ -hydroxysteroid dehydrogenase type 2 at birth, a targeted temporal window for neonatal glucocorticoid action in human and mice. *PLoS One.* 2012;7(2):e31949. [CrossRef](#), [Medline](#)
24. Benediktsson R, Lindsay RS, Noble J, Seckl JR, Edwards CRW. Glucocorticoid exposure in utero: new model for adult hypertension. *Lancet.* 1993;341:339–341. [CrossRef](#)
25. Stewart PM, Rogerson FM, Mason JI. Type 2 11 $\beta$ -hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. *J Clin Endocrinol Metab.* 1995;80(3):885–890. [Abstract](#), [Medline](#)
26. Rogerson FM, Kayes MK, White PC. Variation in placental type 2 11 $\beta$ -hydroxysteroid dehydrogenase activity is not related to birth or placental weight. *Mol Cell Endocrinol.* 1997;128:103–109. [CrossRef](#), [Medline](#)
27. Lindsay RS, Lindsay RM, Edwards CRW, Seckl JR. Inhibition of 11 $\beta$ -hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. *Hypertension.* 1996;27(6):1200–1204. [CrossRef](#), [Medline](#)
28. Holmes MC, Abrahamsen CT, French KL, Paterson JM, Mullins JJ, Seckl JR. The mother or the fetus? 11 $\beta$ -Hydroxysteroid dehydrogenase type 2 null mice provide evidence for direct fetal programming of behavior by endogenous glucocorticoids. *J Neurosci.* 2006;26(14):3840–3844. [CrossRef](#), [Medline](#)
29. Hassan-Smith Z, Stewart PM. Inherited forms of mineralocorticoid hypertension. *Curr Opin Endocrinol Diabetes Obes.* 2011;18(3):177–185. [CrossRef](#), [Medline](#)
30. Knops NB, Monnens LA, Lenders JW, Levchenko EN. Apparent mineralocorticoid excess: time of manifestation and complications despite treatment. *Pediatrics.* 2011;127(6):e1610–e1614. [CrossRef](#), [Medline](#)
31. Weng SF, Redsell SA, Swift JA, Yang M, Glazebrook CP. Systematic review and meta-analyses of risk factors for childhood overweight identifiable during infancy. *Arch Dis Child.* 2012;97(12):1019–1026. [CrossRef](#), [Medline](#)
32. Jinno K, Sakura N, Nomura S, Fujitaka M, Ueda K, Kihara M. Failure of cortisone acetate therapy in 21-hydroxylase deficiency in early infancy. *Pediatr Int.* 2001;43(5):478–482. [CrossRef](#), [Medline](#)
33. Rosenstock J, Banarar S, Fonseca VA, et al. The 11 $\beta$ -hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. *Diabetes Care.* 2010;33(7):1516–1522. [CrossRef](#), [Medline](#)

34. Feig PU, Shah S, Hermanowski-Vosatka A, et al. Effects of an 11 $\beta$ -hydroxysteroid dehydrogenase type 1 inhibitor, MK-0916, in patients with type 2 diabetes mellitus and metabolic syndrome. *Diabetes Obes Metab*. 2011;13(6):498–504. [CrossRef](#), [Medline](#), [ISI](#)
35. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11 $\beta$ -hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. *Proc Natl Acad Sci USA*. 1997;94(26):14924–14929. [CrossRef](#), [Medline](#)
36. Thigpen AE, Davis DL, Milatovich , et al. Molecular genetics of steroid 5 $\alpha$ -reductase 2 deficiency. *J Clin Invest*. 1992;90(3):799–809. [CrossRef](#), [Medline](#)
37. Russell DW, Wilson JD. Steroid 5 $\alpha$ -reductase: two genes/two enzymes. *Annu Rev Biochem*. 1994;63:25–61. [CrossRef](#), [Medline](#)
38. Tomlinson JW, Finney J, Hughes BA, Hughes SV, Stewart PM. Reduced glucocorticoid production rate, decreased 5 $\alpha$ -reductase activity and adipose tissue insulin sensitization following weight loss. *Diabetes*. 2008;57(6):1536–1543. [CrossRef](#), [Medline](#)
39. Westerbacka J, Yki-Jarvinen H, Vehkavaara S, et al. Body fat distribution and cortisol metabolism in healthy men: enhanced 5 $\beta$ -reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver. *J Clin Endocrinol Metab*. 2003;88(10):4924–4931. [Abstract](#), [Medline](#)
40. Tsilchorozidou T, Honour JW, Conway GS. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5 $\alpha$ -reduction but not the elevated adrenal steroid production rates. *J Clin Endocrinol Metab*. 2003;88(12):5907–5913. [Abstract](#), [Medline](#)
41. Kamrath C, Hartmann MF, Remer T, Wudy SA. The activities of 5 $\alpha$ -reductase and 17,20-lyase determine the direction through androgen synthesis pathways in patients with 21-hydroxylase deficiency. *Steroids*. 2012;77(13):1391–1397. [CrossRef](#), [Medline](#)
42. Berry LM, Polk DH, Ikegami M, Jobe AH, Padbury JF, Ervin MG. Preterm newborn lamb renal and cardiovascular responses after fetal or maternal antenatal betamethasone. *Am J Physiol*. 1997;272(6 Pt 2):R1972–R1979. [Medline](#)
43. Ortiz LA, Quan A, Weinberg A, Baum M. Effect of prenatal dexamethasone on rat renal development. *Kidney Int*. 2001;59(5):1663–1669. [CrossRef](#), [Medline](#)
44. Bian X, Seidler FJ, Slotkin TA. Fetal dexamethasone exposure interferes with establishment of cardiac noradrenergic innervation and sympathetic activity. *Teratology*. 1993;47(2):109–117. [CrossRef](#), [Medline](#)
45. Hadoke PW, Lindsay RS, Seckl JR, Walker BR, Kenyon CJ. Altered vascular contractility in adult female rats with hypertension programmed by prenatal glucocorticoid exposure. *J Endocrinol*. 2006;188(3):435–442. [CrossRef](#), [Medline](#)
46. Sloboda DM, Newnham JP, Challis JR. Repeated maternal glucocorticoid administration and the developing liver in fetal sheep. *J Endocrinol*. 2002;175(2):535–543. [CrossRef](#), [Medline](#)
47. Drake AJ, Raubenheimer PJ, Kerrigan D, McInnes KJ, Seckl JR, Walker BR. Prenatal dexamethasone programs expression of genes in liver and adipose tissue and increased hepatic lipid accumulation but not obesity on a high-fat diet. *Endocrinology*. 2010;151(4):1581–1587. [Abstract](#), [Medline](#)
48. Dumortier O, Theys N, Ahn MT, Remacle C, Reusens B. Impairment of rat fetal  $\beta$ -cell development by maternal exposure to dexamethasone during different time-windows. *PLoS One*. 2011;6(10):e25576. [CrossRef](#), [Medline](#)
49. Tang JI, Kenyon CJ, Seckl JR, Nyirenda MJ. Prenatal overexposure to glucocorticoids programs renal 11 $\beta$ -hydroxysteroid dehydrogenase type 2 expression and salt-sensitive hypertension in the rat. *J Hypertens*. 2011;29(2):282–289. [CrossRef](#), [Medline](#)
50. Nyirenda MJ, Carter R, Tang JI, et al. Prenatal programming of metabolic syndrome in the common marmoset is associated with increased expression of 11 $\beta$ -hydroxysteroid dehydrogenase type 1. *Diabetes*. 2009;58(12):2873–2879. [CrossRef](#), [Medline](#)
51. Masuzaki H, Paterson J, Shinyama H, et al. A transgenic model of visceral obesity and the metabolic syndrome. *Science*. 2001;294(5549):2166–2170. [CrossRef](#), [Medline](#), [ISI](#)
52. McKinlay CJ, Crowther CA, Middleton P, Harding JE. Repeat antenatal glucocorticoids for women at risk of preterm birth: a Cochrane systematic review. *Am J Obstet Gynecol*. 2012;206(3):187–194. [CrossRef](#), [Medline](#)

53. Peltoniemi OM, Kari MA, Hallman M. Repeated antenatal corticosteroid treatment: a systematic review and meta-analysis. *Acta Obstet Gynecol Scand.* 2011;90(7):719–727. [CrossRef](#), [Medline](#)
54. Doyle LW, Ford GW, Rickards AL, et al. Antenatal corticosteroids and outcome at 14 years of age in children with birth weight less than 1501 grams. *Pediatrics.* 2000;106(1):E2. [CrossRef](#), [Medline](#)
55. Dalziel SR, Walker NK, Parag V, et al. Cardiovascular risk factors after antenatal exposure to betamethasone: 30-year follow-up of a randomised controlled trial. *Lancet.* 2005;365(9474):1856–1862. [CrossRef](#), [Medline](#)
56. Finken MJ, Keijzer-Veen MG, Dekker FW, et al. Antenatal glucocorticoid treatment is not associated with long-term metabolic risks in individuals born before 32 weeks of gestation. *Arch Dis Child Fetal Neonatal Ed* 2008;93(6):F442–F447. [CrossRef](#), [Medline](#)